B cells for cancer immunotherapy.
We have engineered a novel fusion cytokine named GIFT4 derived from GM-CSF and IL-4, and displaying robust gain-of-function immunostimulatory effects on B cells. GIFT4-programmed B cells have a unique identity and potent capacity to elicit a tumoricidal - cell response, thus comprising a novel B cell-based cancer immunotherapeutic approach.
Department of Hematology and Medical Oncology; Winship Cancer Institute; Emory University ; Atlanta, GA USA.
Jiusheng
J
Deng
Department of Hematology and Medical Oncology; Winship Cancer Institute; Emory University ; Atlanta, GA USA ; Department of Pediatrics; Winship Cancer Institute; Emory University ; Atlanta, GA USA.
Jacques
J
Galipeau
B cells; GIFT4; cancer immunotherapy; fusion cytokine